---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-22-000149"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:24:28.498676+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Evolus amends Daewoong supply pact: exits Russia, revamps Europe pricing

## Summary
- Evolus exits Russia; all rights to neurotoxin distribution revert to Daewoong.
- European pricing changed from fixed transfer price to net-sales-based price with quarterly true-up.
- Transfer price renegotiated annually; floor price per vial set.
- Evolus must meet launch schedule and reporting obligations; failure allows Daewoong to revert pricing.
- Parties to cooperate on transferring Russia regulatory materials to Daewoong.

## SEC filing metadata
- accession: 0001570562-22-000149
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000149/0001570562-22-000149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000149/eols-20221212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-22-000149
- JSON: https://secwatch.observer/filing/0001570562-22-000149.json
- Plain text: https://secwatch.observer/filing/0001570562-22-000149.txt

## Key facts
- Material Agreements
  Evolus, Inc. amended Fourth Amendment to License and Supply Agreement with Daewoong Pharmaceuticals Co., Ltd. (effective 2022-12-12).
  - Action: amendment
  - Agreement: license
  - Counterparty: Daewoong Pharmaceuticals Co., Ltd.
  - Effective: 2022-12-12
  source text: On December 12, 2022, Evolus, Inc., a Delaware corporation (the “Company”), and Daewoong Pharmaceuticals Co., Ltd., a corporation organized and existing under the laws of the Republic of Korea (“Daewoong”) entered into a Fourth Amendment (the “Fourth Amendment”) to that certain License and Supply Agreement (the “Supply Agreement”), originally dated September 30, 2013, as amended.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000149/0001570562-22-000149-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.